Doctors have successfully treated Huntington’s disease for the first time, slowing its progression by 75%. The breakthrough offers hope to thousands affected by the devastating genetic disorder.
In a monumental breakthrough, doctors have successfully treated Huntington’s disease, a devastating genetic condition that affects approximately 41,000 Americans. For the first time, researchers have managed to slow the progression of this disease by as much as 75%, offering hope to those living with the condition.
Huntington’s disease is a progressive disorder that affects a person’s physical, mental, and emotional abilities, combining symptoms of conditions such as dementia, Parkinson’s, and motor neurone disease. The condition is caused by a mutation in a protein called Huntington’s protein, which leads to the death of brain cells. It is hereditary, and children of an affected parent have a 50/50 chance of inheriting the gene.
The breakthrough treatment, developed by a team at University College London, has shown remarkable results. The research involved gene therapy, which was delivered directly into the brain during a complex 12 to 18-hour surgery. A modified virus introduced new genetic instructions, helping brain cells block the harmful protein associated with Huntington’s disease.
Professor Sarah Tabrizi, director of the University College London Huntington’s Disease Centre, called the results “spectacular,” revealing that the treatment had slowed the disease’s progression by 75%. In a groundbreaking trial, patients who would typically experience one year of decline in their condition saw the same level of deterioration over a four-year period.
The study involved 29 patients, and after three years, results showed fewer brain cells dying, with a dramatic slowing of disease progression. Some patients, who had previously been medically retired, were able to return to work, and others remained mobile, even though they were once expected to require a wheelchair.
For individuals like 30-year-old Jack May-Davis, who inherited the Huntington’s gene from his father and grandmother, this breakthrough is life-changing. Watching his father’s health deteriorate until he needed 24/7 care, May-Davis had previously feared a similar fate. After participating in the clinical trial, he expressed how overwhelmed he was by the possibility of a longer life. “It does allow me to think my life could be that much longer,” he said.
While the therapy is expected to be costly and may not be suitable for all patients, researchers are hopeful it could provide long-term benefits. The company behind the treatment, UniQure, plans to apply for accelerated approval from the U.S. Food and Drug Administration (FDA) early next year, with applications for approval in the UK and Europe to follow.
